argenx to acquire Forte Biosciences for $77/share (~$2.2B); adds anti-CD122 antibody FB102

Forte Biosciences, Inc.

argenx to acquire Forte Biosciences for $77/share in cash, total equity value ~$2.2B.
Offer price represents ~86% premium to Forte's VWAP since positive Phase 1b vitiligo data on July 9, 2026.
Acquisition adds first-in-class anti-CD122 antibody FB102 with clinical proof-of-concept in vitiligo and celiac disease.
Forte board unanimously recommends; tender offer requires majority of shares tendered and HSR clearance.
Supporting stockholders (directors/officers) owning ~1% of shares have agreed to tender.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.